Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The new campus has been designed as an employee-centred experience and ecosystem zone
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Lays foundation stone of NIPER Hyderabad and NIPER Raebareli
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
He is also inducted as a member of the management council and senior management personnel of the company
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Subscribe To Our Newsletter & Stay Updated
